Marques Tiago 4/A
4/A · Pasithea Therapeutics Corp. · Filed Apr 5, 2024
Insider Transaction Report
Form 4/AAmended
Marques Tiago
DirectorChief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2024-03-01+15,000→ 15,000 totalExercise: $8.13Exp: 2034-02-28→ Common Stock (15,000 underlying) - Award
Stock Option (right to buy)
2024-03-01+11,669→ 11,669 totalExercise: $8.13Exp: 2034-02-28→ Common Stock (11,669 underlying)
Footnotes (3)
- [F1]The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
- [F2]The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date.
- [F3]The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024.